Lab Add.

: Sevoke Road, Siliguri 734001

Patient Name : VINOD KUMAR

Ref Dr. : Dr.MEDICAL OFFICER

Age : 40 Y 3 M 14 D **Gender** : M

 Collection Date
 : 08/Mar/2025 11:39AM

 Report Date
 : 08/Mar/2025 01:57PM



DEFACTOR DIOCHEMISTRY			
Test Name	Result	Bio Ref. Interval	Unit
SODIUM,BLOOD , GEL SERUM (Method:ISE INDIRECT)	138	136 - 145	mEq/L
*BILIRUBIN (TOTAL) , GEL SERUM			
BILIRUBIN (TOTAL) (Method:DIAZONIUM ION)	<u>1.25</u>	0.2 - 1.2	mg/dL
*THYROID PANEL (T3, T4, TSH), GEL SERUM	1		
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.06	0.60 - 1.81	ng/mL
T4-TOTAL (THYROXINE) (Method:CLIA)	7.6	4.5 - 10.9	microgram/dl
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	2.21	0.35 - 5.5	μlU/mL

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL
THIRD TRIMESTER : 0.30 3.00 µ IU/mL

References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

ALKALINE PHOSPHATASE (Method:P-NPP,AMP BUFFER)	105	46 - 116	U/L
SGOT/AST (Method:UV WITH P5P)	30	15 - 37	U/L
SGPT/ALT (Method:UV WITH P5P)	34	16- 63	U/L
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4	3.5 - 5.1	mEq/L
UREA,BLOOD (Method:UREASE-COLORIMETRIC)	15	12.8 - 42.8	mg/dl
GLUCOSE,FASTING (Method:HEXOKINASE)	86	70 - 100	mg/dL
CALCIUM,BLOOD (Method:OCPC)	8.63	8.6-10.0	mg/L
URIC ACID,BLOOD (Method:URICASE ,COLORICMETRIC)	4.7	3.5 - 7.2	mg/dL

: Sevoke Road, Siliguri 734001 Lab Add.

: Dr.MEDICAL OFFICER

Patient Name : VINOD KUMAR

: 40 Y 3 M 14 D

Collection Date : 08/Mar/2025 11:39AM

Gender

Report Date : 08/Mar/2025 01:57PM



Ref Dr.

est Name	Result	Bio Ref. Interval	Unit	
TOTAL PROTEIN [BLOOD] ALB:	GLO RATIO,			
TOTAL PROTEIN (Method:BIURET METHOD)	7.28	6.6 - 8.7	g/dL	
ALBUMIN (Method:BCP)	4.1	3.4-5.0	g/dL	
GLOBULIN (Method:Calculated)	<u>3.21</u>	1.8-3.2	g/dL	
AG Ratio (Method:Calculated)	1.27	1.0 - 2.5		

VLDL 20 (Method:Calculated) CHOL HDL Ratio 3.7 (Method:Calculated) NON-HDL CHOLESTEROL 104. (Method:Calculated) BILIRUBIN (DIRECT) 0.22 (Method:DIAZOTIZATION)		mg/dL
(Method:Calculated) CHOL HDL Ratio 3.7 (Method:Calculated) NON-HDL CHOLESTEROL 104.	AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	mg/dL
(Method:Calculated) CHOL HDL Ratio (Method:Calculated) 3.7	AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	
	< 40	mg/dL
LDL CHOLESTEROL DIRECT 84 (Method:DIRECT MEASURE)	Optimal : <100, Above optimal : 100-129, Borderline High : 130-159, High : 160-189, Very High : >=190	mg/dL e
HDL CHOLESTEROL 39 (Method:DIRECT MEASURE-PEG)	NO RISK : >60, MODERATE RISK : 40-60, HIGH RISK : <40	mg/dL
TRIGLYCERIDES 132 (Method:ENZYMATIC, END POINT)	NORMAL: < 150, BORDERLINE HIGH: 150-199, HIGH 200-499, VERY HIGH: > 500	mg/dL H:
CHOLESTEROL-TOTAL 143 (Method:CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE)	Desirable: < 200, Borderline high: 200-239, High: > 240	mg/dL

CREATININE, BLOOD	0.83	0.7 - 1.3	mg/L
(Method: ALKALINE PICRATE)			
*GLYCATED HAEMOGLOBIN (HBA1C),	EDTA WHOLE BLOOD		
GLYCATED HEMOGLOBIN (HBA1C)	5.5	***For biological reference interval,	%

OLIONIED HALMOGEODIN (HDATO), LE	TA WHOLL BLOOD		
GLYCATED HEMOGLOBIN (HBA1C)	5.5	***For biological reference interval, please refer to the below mentioned remarks ***	%
HbA1c (IFCC) (Method:HPLC)	36		mmol/mol

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

> **Lab No.** : SG2/08-03-2025/MR0441326 Page 2 of 11



Lab Add.

: Sevoke Road, Siliguri 734001

Patient Name

Gender

: VINOD KUMAR

Ref Dr.

: Dr.MEDICAL OFFICER

Age : 40 Y 3 M 14 D

Collection Date

: 08/Mar/2025 11:39AM

Report Date

: 08/Mar/2025 01:57PM



Test Name Result Bio Ref. Interval Unit

Analyzer used : Bio-Rad D 10 Method : HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached

PHOSPHORUS-INORGANIC,BLOOD (Method:UV PHOSPHOMOLYBDATE)	3.5	2.5 - 4.5	mg/dL	
CHLORIDE,BLOOD (Method:ISE INDIRECT)	104	98 - 107	mEq/L	

*** End Of Report ***

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Lab No. : SG2/08-03-2025/MR0441326 Page 3 of 11







 Patient Name
 : VINOD KUMAR
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 40 Y 3 M 14 D
 Collection Date
 : 08/Mar/2025 11:59AM

 Gender
 : M
 Report Date
 : 10/Mar/2025 12:16PM



DEPARTMENT OF BIOCHEMISTRY

Test Na	me	Result	Bio Ref. Interval	Unit
URIC AC	CID, URINE, SPOT URINE			
	ACID, SPOT URINE I:Uricase/Peroxidase)	11	06-114 mg/dl	mg/dl

*** End Of Report ***

DR. ANANNYA GHOSH MBBS, MD (Biochemistry) Consultant Biochemist Reg No. WBMC 73007

Lab No. : SG2/08-03-2025/MR0441326



Lab Add.

: Sevoke Road, Siliguri 734001

Patient Name : VINOD KUMAR

Age : 40 Y 3 M 14 D

Ref Dr.

: Dr.MEDICAL OFFICER

Gender : M

Collection Date
Report Date

: 08/Mar/2025 11:39AM : 08/Mar/2025 04:21PM



Test Name	Result	Bio Ref. Interval	Unit	

CBC WITH PLATELET (THROMBOCYTE)	COUNT, EDTA WHOLE BLO	OD	
HEMOGLOBIN	14	13 - 17	g/dL
(Method:SLS haemoglobin method)			
WBC	5	4 - 10	x10^3/µL
(Method:Impedance) RBC	5.09	4.5 - 5.5	x10^6/μL
(Method:Impedance)	5.09	4.5 - 5.5	χ10-6/μΕ
PLATELET	174	150-450	x10^3/µL
(Method:Impedance/Microscopy)		.00 .00	o.p.
DIFFERENTIAL COUNT			
NEUTROPHILS	45	40 - 80	%
(Method:Flowcytometry/Microscopy)			
LYMPHOCYTES	<u>52</u>	20 - 40	%
(Method:Flowcytometry/Microscopy)	00	0.40	0/
MONOCYTES (Method:Flowcytometry/Microscopy)	02	2 - 10	%
EOSINOPHILS	01	1 - 6	%
(Method:Flowcytometry/Microscopy)	01	1 0	76
BASOPHILS	00	0-0.9	%
(Method:Impedance/Microscopy)			
CBC SUBGROUP			
HEMATOCRIT / PCV	44.2	40 - 50	%
(Method:Calculated)			_
MCV	87	83 - 101	fL
(Method:Calculated) MCH	27.6	27 - 32	ng
(Method:Calculated)	21.0	21 - 32	pg
MCHC	31.7	31.5-34.5	g/dL
(Method:Calculated)			_
RDW - RED CELL DISTRIBUTION WIDTH	<u>16.5</u>	11.6-14	%
(Method:Calculated)	00.0	0.0.05	
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	30.6	8.3 - 25	fL
MPV-MEAN PLATELET VOLUME	13.5	7.5 - 11.5	fL
(Method:Calculated)	10.0	7.0 11.0	<u>. </u>
RBC	Normocytic		
	normochromic.		
WBC.	Normal in number &		
	morphology.		
PLATELET	Adequate.		

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

(Method:Column Agglutination)

Ь

Rh

Positive

(Method:Column Agglutination)

Gel technology Dia Med ID Micro typing system is the latest technology in transfusion Medicine.

It gives more reproducible and standardized test results.

It more repaid, reliable, very sensitive and objective, and hence more consistent and comparable results are obtained. Single used cards are individualised for every patient and results can be photographed / scanned and stored for future use.

Special instruments that are used only for this technology also reduce risk of any contamination.

Ref:- WHO technical manual on transfusion medicine-Second Edition 2003

Lab No. : SG2/08-03-2025/MR0441326



Lab No. : SG2/08-03-2025/MR0441326 Lab Add. : Sevoke Road, Siliguri 734001

Patient Name Ref Dr. : Dr.MEDICAL OFFICER : VINOD KUMAR Age : 40 Y 3 M 14 D **Collection Date** : 08/Mar/2025 11:39AM : 08/Mar/2025 04:21PM Gender : M **Report Date**



DEPARTMENT OF HAEMATOLOGY

Test Name Bio Ref. Interval Result Unit

(RESULTS ALSO VERIFIED BY : FORWARD AND REVERSE GROUPING (TUBE AND SLIDE METHOD)

Advantages:

- Column agglutination by gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Note: Historical records check not performed.

(Method:Modified Westergren Method)

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

10 0.0 - 20mm/hr

*** End Of Report ***

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Page 6 of 11 Lab No. SG2/08-03-2025/MR0441326



Lab Add.

: Sevoke Road, Siliguri 734001

Patient Name : VINOD KUMAR Ref Dr.

: Dr.MEDICAL OFFICER

: 40 Y 3 M 14 D Gender : M

Collection Date Report Date

: 08/Mar/2025 11:48AM : 08/Mar/2025 04:23PM



Bio Ref. Interval **Test Name** Result Unit

URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
CHEMICAL EXAMINATION			
pH	6.5	4.6 - 8.0	
(Method:Dipstick (triple indicator method))			
SPECIFIC GRAVITY	1.010	1.005 - 1.030	
(Method:Dipstick (ion concentration method))	ADOENIT	NOT DETECTED	
PROTEIN (Method:Dipstick (protein error of pH	ABSENT	NOT DETECTED	
indicators)/Manual)			
GLUCOSE	ABSENT	NOT DETECTED	
(Method:Dipstick(glucose-oxidase-peroxidase			
method)/Manual)			
KETONES (ACETOACETIC ACID,	ABSENT	NOT DETECTED	
ACETONE) (Method:Dipstick (Legals test)/Manual)			
BLOOD	ABSENT	NOT DETECTED	
(Method:Dipstick (pseudoperoxidase reaction))	ADOLIVI	NOT BETEGTED	
BILIRUBIN	ABSENT	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)			
UROBILINOGEN	ABSENT	NEGATIVE	
(Method:Dipstick (diazonium ion reaction)/Manual)	4 D O E N I T	NEO 4 TV (5	
NITRITE (Mathed Directicle (Gricon toot))	ABSENT	NEGATIVE	
(Method:Dipstick (Griess test)) LEUCOCYTE ESTERASE	ABSENT	NEGATIVE	
(Method:Dipstick (ester hydrolysis reaction))	ADOLIVI	NEOATIVE	
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	1-2	0-5	/hpf
(Method:Microscopy)	-		• 1
EPITHELIAL CELLS	0-1	0-5	/hpf
(Method:Microscopy)			
RED BLOOD CELLS	ABSENT	0-2	/hpf
(Method:Microscopy)	ADCENT	NOT DETECTED	
CAST (Method:Microscopy)	ABSENT	NOT DETECTED	
CRYSTALS	ABSENT	NOT DETECTED	
(Method:Microscopy)	· · · ·		
BACTERIA	ABSENT	NOT DETECTED	
(Method:Microscopy)			
YEAST	ABSENT	NOT DETECTED	
(Method:Microscopy)	ADCENT		
OTHERS	ABSENT		

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.

 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by

: SG2/08-03-2025/MR0441326 Lab No.

Page 7 of 11



Lab No. Lab Add. : SG2/08-03-2025/MR0441326 : Sevoke Road, Siliguri 734001

Patient Name Ref Dr. : Dr.MEDICAL OFFICER : VINOD KUMAR : 40 Y 3 M 14 D **Collection Date** : 08/Mar/2025 11:48AM Gender : 08/Mar/2025 04:23PM **Report Date**



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Bio Ref. Interval Unit

microscopy can occur due to cell lysis.

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

*** End Of Report ***

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Page 8 of 11 SG2/08-03-2025/MR0441326 Lab No.

Patient Name : VINOD KUMAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 40 Y 3 M 14 D Collection Date :

 Gender
 : M
 Report Date
 : 08/Mar/2025 05:02PM



DEPARTMENT OF ULTRASONOGRAPHY REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER

Liver is normal in size (125 mm) having normal shape, regular smooth outline and of homogeneous echotexture. No focal parenchymal lesion is evident. Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

PORTA

The appearance of porta is normal. Common Bile duct is normal with no intraluminal pathology (Calculi /mass) could be detected at its visualised part. Portal vein is normal at porta.

GALL BLADDER

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected. Sonographic Murphys sign is negative.

PANCREAS

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

SPLEEN

Spleen is normal in size (86 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

KIDNEYS

Both kidneys are normal in shape, size (Rt. kidney 96 mm. & Lt. kidney 107 mm) axes & position. Cortical echogenecity appears normal maintaining corticomedullary differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected.

URETERS

Visualised part of upper ureters are not dilated.

URINARY BLADDER

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi / mass) could be detected.

PROSTATE

Prostate is mildly enlarged in size. Echotexture appears within normal limits. No focal alteration of its echogenecity could be detectable.

It measures : 38 x 40 x 31 mm.

Approximate weight could be around = 25 gms.

IMPRESSION

Grade I prostatomegaly.

(Please correlate clinically & with other investigation. Follow up suggested).

Kindly note

- ▶ Ultrasound is not the modality of choice to rule out subtle bowel lesion.
- ➤ Please Intimate us for any typing mistakes and send the report for correction within 7 days.
- The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and

Lab No. : SG2/08-03-2025/MR0441326 Page 9 of 11

Lab Add.

Ref Dr.

Report Date

: Dr.MEDICAL OFFICER

.ge : 40 Y 3 M 14 D

Patient Name

Collection Date

: 08/Mar/2025 05:02PM

Gender : M

: VINOD KUMAR

radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

*** End Of Report ***

Dr.Md Quamar Reza M.B.B.S., CBET(Sonologist) Reg No: 78950(WBMC)

Lab No. : SG2/08-03-2025/MR0441326 Page 10 of 11

: SG2/08-03-2025/MR0441326 Lab No.

: VINOD KUMAR

Lab Add. Ref Dr.

: 40 Y 3 M 14 D

: M

Patient Name

Gender

: Dr.MEDICAL OFFICER

Collection Date

: 08/Mar/2025 05:03PM **Report Date**



DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

HEART RATE 67 /min.

RHYTHM Regular sinus.

P-WAVE Normal

P-R INTERVAL 160 ms, **QRS DURATION** 80 ms **QRS CONFIGURATION NORMAL**

QRS VOLTAGE R/S in V1 5/6 mm.

> R/S in V6 19/5 mm.

QRS AXIS NORMAL

Q- Waves No significant Q-wave.

QT TIME Normal.

ST SEGMENT Normal.

T WAVE **NORMAL**

ROTATION Normal.

OTHER FINDINGS Nil.

IMPRESSION SINUS RYTHM, LEFT AXIS DEVIATION.

> DR. PRAJJAL KUMAR SINHA MBBS, MD (General Medicine)


DM Cardiology WBMC - 69828

Page 11 of 11 **Lab No.** : SG2/08-03-2025/MR0441326

Patient report

Sample ID: E02132177901

Injection date 08/03/2025 11:55 PM
Injection #: 15 D-10 Method: HbA1c
Rack #: --- Rack position: 5



Peak table - ID: E02132177901

Peak	R.time	Height	Area	Area %
A1a	0.15	4745	17350	0.6
Unknown	0.23	5490	17344	0.6
A1b	0.29	9781	37119	1.3
F	0.52	1684	8013	0.3
LA1c/CHb-1	0.65	6096	48852	1.7
A1c	0.85	13888	112786	5.5
P3	1.30	38597	161424	5.6
A0	1.39	1044076	2494564	86.1

Total Area: 2897452

Concentration:	%	mmol/mol
A1c	5.5	36